Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Agios Pharmaceuticals (AGIO) EPS (Weighted Average and Diluted): 2019-2024

Historic EPS (Weighted Average and Diluted) for Agios Pharmaceuticals (AGIO) over the last 6 years, with Dec 2024 value amounting to $11.64.

  • Agios Pharmaceuticals' EPS (Weighted Average and Diluted) fell 110.97% to -$1.78 in Q3 2025 from the same period last year, while for Sep 2025 it was -$7, marking a year-over-year decrease of 161.62%. This contributed to the annual value of $11.64 for FY2024, which is 283.89% up from last year.
  • According to the latest figures from FY2024, Agios Pharmaceuticals' EPS (Weighted Average and Diluted) is $11.64, which was up 283.89% from -$6.33 recorded in FY2023.
  • Agios Pharmaceuticals' 5-year EPS (Weighted Average and Diluted) high stood at $26.55 for FY2021, and its period low was -$6.33 during FY2023.
  • Moreover, its 3-year median value for EPS (Weighted Average and Diluted) was -$4.23 (2022), whereas its average is $0.36.
  • As far as peak fluctuations go, Agios Pharmaceuticals' EPS (Weighted Average and Diluted) spiked by 656.60% in 2021, and later crashed by 115.93% in 2022.
  • Yearly analysis of 5 years shows Agios Pharmaceuticals' EPS (Weighted Average and Diluted) stood at -$4.77 in 2020, then soared by 656.60% to $26.55 in 2021, then tumbled by 115.93% to -$4.23 in 2022, then tumbled by 49.65% to -$6.33 in 2023, then surged by 283.89% to $11.64 in 2024.